The experience of going through multiple rounds of antidepressant treatment without achieving adequate relief is one of the most demoralising patterns in medicine. Each new prescription arrives with a measure of hope. The waiting period passes. The response is insufficient. The cycle repeats. For the significant minority of patients with major depressive disorder for whom this is the lived experience, knowing what comes after the standard pathway is not just useful information — it is essential.
The options available to patients with treatment-resistant depression have expanded meaningfully over the past decade. Understanding what those options are, how they compare, and how to access them in New York City is the subject of this article.
Defining the Problem
Treatment-resistant depression is typically defined as a failure to achieve adequate improvement after at least two antidepressant trials at therapeutic doses for adequate durations. By this definition, somewhere between 30 and 50 percent of people with major depressive disorder will qualify — not because depression itself is intractable, but because the conventional pharmacological toolkit does not work for everyone.
The reasons for treatment resistance are varied and not fully understood. They include pharmacogenomic factors that affect how individuals metabolise and respond to specific medications, the presence of comorbid conditions such as anxiety disorders, ADHD, or trauma that complicate the depression, inadequate treatment in previous trials due to subtherapeutic doses or insufficient duration, and genuinely refractory neurobiological patterns that do not respond to monoamine-targeting agents.
Identifying the reasons for treatment resistance, rather than simply switching medications again, is one of the most valuable things a specialist psychiatrist can do for a patient in this situation. Understanding why previous treatments have not worked informs which alternatives are most likely to be effective.
TMS as a First-Line Specialist Option
For patients who meet the clinical criteria for treatment-resistant depression, transcranial magnetic stimulation is typically the first specialist intervention to consider. It is FDA-cleared, has a strong evidence base, is covered by most major insurance plans for eligible patients, and carries a favourable safety profile that makes it an appropriate first step for most patients entering specialist care.
Village TMS treatment programmes are designed around this clinical context. Every patient who receives TMS at Village TMS begins with a comprehensive psychiatric evaluation that establishes the full diagnostic picture, reviews the history of previous treatments, identifies any factors that might affect treatment response, and designs a protocol that reflects the individual’s specific clinical profile rather than a standard template.
The evidence for TMS in treatment-resistant depression is now extensive. Response rates in clinical practice, meaning clinically meaningful improvement in depressive symptoms, are typically in the range of 50 to 60 percent for patients completing a full course of treatment. Remission rates, meaning essentially complete resolution of depressive symptoms, are lower but represent a meaningful proportion of those who respond. For patients who have tried multiple medications without benefit, these figures represent a genuine reason for optimism.
According to the National Institute of Mental Health, treatment-resistant depression is one of the most significant unmet needs in psychiatry, and specialist interventions including TMS have substantially improved the options available for this population over the past decade.
Ketamine for Depression: When TMS Is Not Sufficient
For patients who do not achieve adequate benefit from TMS, or for whom the clinical situation requires a faster response than TMS can provide, ketamine-based treatments represent the next tier of specialist care. The evidence for ketamine in treatment-resistant depression is compelling: response rates of 50 to 70 percent in patients who have failed multiple prior treatments have been consistently reported across multiple research settings.
The speed of ketamine’s effect is its most clinically distinctive feature. Where TMS typically requires several weeks to produce its full benefit, ketamine can produce meaningful improvements in mood within hours to days of administration. For patients in acute distress or for those who have been waiting too long for relief, this speed of onset is clinically significant rather than merely convenient.
For patients in New York City seeking ketamine depression treatment within a comprehensive specialist psychiatric service, Village TMS offers both IV ketamine infusion and Spravato, with treatment decisions guided by each patient’s specific clinical history, current situation, and insurance coverage. Their team does not apply a standard algorithm but makes individualised recommendations that reflect genuine clinical thinking.
Building a Complete Treatment Programme
For most patients with treatment-resistant depression, the most effective approach is not a single intervention but a coordinated programme that may include TMS, ketamine, ongoing medication management, and psychotherapy working in concert. The neurobiological changes produced by TMS and ketamine create windows of opportunity for the kind of therapeutic work that supports durable recovery, and patients who engage with the full programme typically achieve better and more lasting outcomes than those who pursue any single element in isolation.
Village TMS is built around this comprehensive model. Their team coordinates across all dimensions of a patient’s care, ensuring that the specialist interventions they deliver are embedded in a broader clinical programme that maximises the chances of meaningful, sustained improvement. If you have been living with depression that has not responded adequately to standard treatment, Village TMS is ready to help you explore what comes next. Contact them today to schedule your evaluation.
Maintaining Gains After Treatment
One dimension of treatment-resistant depression management that deserves specific attention is what happens after an acute treatment programme ends. Both TMS and ketamine can produce meaningful and durable improvements in depression, but the question of how to maintain those gains over the long term is clinically important. For TMS, maintenance treatment — less frequent booster sessions delivered at regular intervals — can help sustain the benefits of the initial course for patients whose response begins to fade over time. For ketamine, a similar maintenance infusion model applies. The clinical team at Village TMS plans for the maintenance phase from the outset, ensuring that patients have a clear strategy for sustaining their response rather than simply waiting to see what happens after the acute programme ends.
